Search research articles
Contact Us
Filters
Showing results (51-60 of 169) with videos related to
Page
of 17
Sort By:
Oncology (Williston Park, N.Y.)
|
June 9, 2001
Dose-dense and sequential strategies in adjuvant breast cancer therapy
M Untch, F Von Koch, C Crohns, et al.
Gynakologisch-Geburtshilfliche Rundschau
|
January 1, 1993
[Prognostic value of tumor cells in bone marrow in breast cancer]
M Untch, C Nestle-Krämling, G Konecny, et al.
Cancer Investigation
|
January 1, 1993
In vitro evaluation of the novel chemotherapeutic agents U-73,975, U-77,779, and U-80,244 in gynecologic cancer cell lines
R D Hightower, B U Sevin, J Perras, et al.
Clinical Chemistry and Laboratory Medicine
|
August 28, 2001
Nucleosomes in serum as a marker for cell death
S Holdenrieder, P Stieber, H Bodenmüller, et al.
European Journal of Nuclear Medicine
|
July 7, 2001
18F-FDG PET and 99mTc-sestamibi scintimammography for monitoring breast cancer response to neoadjuvant chemotherapy: a comparative study
R Tiling, R Linke, M Untch, et al.
Der Radiologe
|
January 10, 1998
[MR mammography. Preoperative marking of non-palpable breast lesions with the Magnetom open at 0.2 T]
H Sittek, C Perlet, K Herrmann, et al.
Seminars in Oncology
|
November 28, 1997
Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer
H J Lück, C Thomssen, A du Bois, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 24, 2001
Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization
A Lebeau, D Deimling, C Kaltz, et al.
Oncology (Williston Park, N.Y.)
|
April 1, 1997
Paclitaxel and epirubicin as first-line therapy for patients with metastatic breast cancer
H J Lück, A Du Bois, C Thomssen, et al.
Oncology (Williston Park, N.Y.)
|
March 28, 1998
Metastatic breast cancer: experience with the combination paclitaxel plus epirubicin
H J Lück, C Thomssen, A Du Bois, et al.
Page
of 17
Search research articles
Search
Showing results (51-60 of 169) with videos related to
Sort By:
Page
of 17
Oncology (Williston Park, N.Y.)
|
June 9, 2001
Dose-dense and sequential strategies in adjuvant breast cancer therapy
M Untch, F Von Koch, C Crohns, et al.
Gynakologisch-Geburtshilfliche Rundschau
|
January 1, 1993
[Prognostic value of tumor cells in bone marrow in breast cancer]
M Untch, C Nestle-Krämling, G Konecny, et al.
Cancer Investigation
|
January 1, 1993
In vitro evaluation of the novel chemotherapeutic agents U-73,975, U-77,779, and U-80,244 in gynecologic cancer cell lines
R D Hightower, B U Sevin, J Perras, et al.
Clinical Chemistry and Laboratory Medicine
|
August 28, 2001
Nucleosomes in serum as a marker for cell death
S Holdenrieder, P Stieber, H Bodenmüller, et al.
European Journal of Nuclear Medicine
|
July 7, 2001
18F-FDG PET and 99mTc-sestamibi scintimammography for monitoring breast cancer response to neoadjuvant chemotherapy: a comparative study
R Tiling, R Linke, M Untch, et al.
Der Radiologe
|
January 10, 1998
[MR mammography. Preoperative marking of non-palpable breast lesions with the Magnetom open at 0.2 T]
H Sittek, C Perlet, K Herrmann, et al.
Seminars in Oncology
|
November 28, 1997
Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer
H J Lück, C Thomssen, A du Bois, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 24, 2001
Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization
A Lebeau, D Deimling, C Kaltz, et al.
Oncology (Williston Park, N.Y.)
|
April 1, 1997
Paclitaxel and epirubicin as first-line therapy for patients with metastatic breast cancer
H J Lück, A Du Bois, C Thomssen, et al.
Oncology (Williston Park, N.Y.)
|
March 28, 1998
Metastatic breast cancer: experience with the combination paclitaxel plus epirubicin
H J Lück, C Thomssen, A Du Bois, et al.
Page
of 17